Nope. It's pretty confusing interpreting these studies sometimes. Results in clinical studies always include primary outcome measures and secondary outcome measures. The secondary outcome looks at use of ivermectin for more serious cases of covid-19 and when people are at the point of requiring mechanical ventilation. There is poor evidence to show ivermectin is beneficial past early stages... This Table 4 only refers to the information provided from 2 studies that were analysed for secondary outcomes.
For primary outcome (death from covid-19) measures, the 15 included clinical trials found that
"ivermectin reduced the risk of death by an average of 62% compared with no ivermectin treatment ".
The evidence of this data was judged as MODERATE.
Evidence when grading quality of research is put into 4 standard categories. 'Moderate' being second after 'high'. Moderate definition means they believe that the true effect is probably close to the estimated effect.
View attachment 1144830
View attachment 1144828